Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Hepatectomy for Stage B and Stage C Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer Classification

Hepatectomy for Stage B and Stage C Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer... ORIGINAL ARTICLE Hepatectomy for Stage B and Stage C Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer Classification Results of a Prospective Analysis Guido Torzilli, MD, PhD; Matteo Donadon, MD; Matteo Marconi, MD; Angela Palmisano, MD; Daniele Del Fabbro, MD; Antonino Spinelli, MD; Florin Botea, MD; Marco Montorsi, MD Hypothesis: Using an algorithm for selection of pa- Results: Hospital mortality was 0.9%. The overall mor- tients with hepatocellular carcinoma (HCC) for sur- bidity was 27.4%, and major morbidity was 3.5%. After gery, Barcelona Clinic Liver Cancer (BCLC) classifica- a median follow-up of 24 months (range, 1-65 months), tion stage B and stage C disease is not a contraindication. there was no cut edge recurrence. For patients with BCLC stages 0 or A, B, and C disease, the 3-year overall sur- Design: Prospective cohort study. vival rates were 81%, 67%, and 74%, respectively (P=.24); the 3-year disease-free survival rates were 30%, 35%, and Setting: University tertiary care hospital. 15%, respectively (P=.85); and the 3-year hepatic disease- Patients: Among 163 consecutive patients with HCC, free survival rates were 39%, 44%, and 17%, respec- 120 (73.6%) underwent surgery; 113 of 120 (94.2%) un- tively (P=.79). derwent resection. Of 113 patients, 61 (54.0%) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Surgery American Medical Association

Hepatectomy for Stage B and Stage C Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer Classification

Loading next page...
 
/lp/american-medical-association/hepatectomy-for-stage-b-and-stage-c-hepatocellular-carcinoma-in-the-okcg5TvSkb
Publisher
American Medical Association
Copyright
Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6254
eISSN
2168-6262
DOI
10.1001/archsurg.143.11.1082
pmid
19015467
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Hepatectomy for Stage B and Stage C Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer Classification Results of a Prospective Analysis Guido Torzilli, MD, PhD; Matteo Donadon, MD; Matteo Marconi, MD; Angela Palmisano, MD; Daniele Del Fabbro, MD; Antonino Spinelli, MD; Florin Botea, MD; Marco Montorsi, MD Hypothesis: Using an algorithm for selection of pa- Results: Hospital mortality was 0.9%. The overall mor- tients with hepatocellular carcinoma (HCC) for sur- bidity was 27.4%, and major morbidity was 3.5%. After gery, Barcelona Clinic Liver Cancer (BCLC) classifica- a median follow-up of 24 months (range, 1-65 months), tion stage B and stage C disease is not a contraindication. there was no cut edge recurrence. For patients with BCLC stages 0 or A, B, and C disease, the 3-year overall sur- Design: Prospective cohort study. vival rates were 81%, 67%, and 74%, respectively (P=.24); the 3-year disease-free survival rates were 30%, 35%, and Setting: University tertiary care hospital. 15%, respectively (P=.85); and the 3-year hepatic disease- Patients: Among 163 consecutive patients with HCC, free survival rates were 39%, 44%, and 17%, respec- 120 (73.6%) underwent surgery; 113 of 120 (94.2%) un- tively (P=.79). derwent resection. Of 113 patients, 61 (54.0%)

Journal

JAMA SurgeryAmerican Medical Association

Published: Nov 1, 2008

References